(FRCP, MBBS, MA Cantab, MRes, PGCE) Consultant in Endocrinology, Diabetes and Internal Medicine Imperial College Healthcare NHS Trust and an Honorary Senior Clinical Lecturer at Imperial College London.
In 2019 she was appointed Head of Specialty for Diabetes at Imperial College Healthcare NHS Trust.
Vassiliki graduated from Cambridge University with an MA (Honours) degree in medical sciences in 2000. She then completed her clinical training at Imperial College London, where she obtained her MBBS degree in 2003. Her postgraduate training was based in teaching hospitals and district general hospitals in North West London. In 2008 she was awarded a National Institute of Health Research (NIHR) Academic Clinical Fellowship in Diabetes and Endocrinology, based at Imperial College London. In 2011, she completed a fellowship in postgraduate medical education with the London deanery and in 2012 she obtained her MRes in Translational Medicine from Imperial College. Her clinical research was based at Imperial College between the department of investigative sciences at Hammersmith Hospital and the department of metabolic medicine at St Mary’s Hospital.
Vassiliki has been a Consultant at St Mary’s Hospital, London since April 2015. From 2017 to 2019, she served as Co-Chair for the North West London Diabetes Foot Sustainability and Transformation Partnership, which aims to develop comprehensive foot care pathways starting from the day of the diagnosis of diabetes, across the Sector, and improve outcomes for people with diabetic foot disease. She is also North West London Regional Lead for the implementations of TEAMeD-5, which aims to improve the outcomes of people with thyroid eye disease, through early diagnostics and interventions that include novel therapies.
In her current role, Vassiliki practises as a full-time NHS Consultant at St Mary’s Hospital and carries out translational research with a focus on diabetic foot disease and thyroid eye disease. Since 2017, she has been a Flow Coach with the Flow Coaching Academy, which exists to enable staff in every healthcare organisation to continuously improve patient care and experience. She holds a level 4 Local Clinical Excellence award at Imperial College Healthcare NHS Trust and is a Fellow of the Royal College of Physicians. As Head of Specialty in Diabetes within her organisation, Vassiliki is working on delivering safe diabetes care, with equity and wise investment, through good examples of integrated care models and digital transformation innovation.
Papers
- Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) afects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study
- Chronic complications versus glycaemic variability, time in range and HbAlc in people with type 1 diabetes: sub study of the RESCUE-trial
- COVID-19 and type 1 diabetes: dealing with the difficult duo
- COVID-19 and Type 1 Diabetes: Concerns and Challenges
- Comparison of Diabetic Ketoacidosis in Adults During the SARS-CoV-2 Outbreak and Over the Same Time Period for the Preceding 3 Years
- Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals
- Diabetes, infection risk and COVID-19
- Cardiovascular Risk in Type 1 Diabetes Mellitus
- Young adult patients with type 1 diabetes have a higher risk of mortality than those of similar age with type 2 diabetes: A nationwide analysis in Hungary
- Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
- Lipid management for cardiovascular risk reduction in type 1 diabetes
- Standard mortality rates and years of life lost for serologically defined adult-onset type 1 and type 2 diabetes – A fifteen year follow-up
- Empagliflozin as Adjunctive to InsulinTherapyinType 1Diabetes: The EASE Trials
- Dapaglifozin: A Review in Type 1 Diabetes
- An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes
- International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
- Sotaglifozin: A Review in Type 1 Diabetes
- Empagliflozin in type 1 diabetes
- Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
- Effi cacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insuffi cient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
- Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
- Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
- Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression
- Type 1 Diabe tes in P regnancy
- 172-LB: Risk of Major Congenital Malformations, Perinatal or Neonatal Death with Insulin Detemir Compared with Other Basal Insulins in Pregnant Women with Preexisting Diabetes: The EVOLVE Study
- Research: Pregnancy Modelling potential cost savings from use of real-time continuous glucose monitoring in pregnant women with Type 1 diabetes
- 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetesd2020
- Automated Insulin Delivery in Child ren wi th Type 1 Diabetes
- A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
- Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
- Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
- Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
- Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes
- Time in range: a new parameter to evaluate blood glucose control in patients with diabetes
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
- The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening
